Journal Watch · Cell · 2026
A GPX1-OSBPL8 axis mediates noncanonical in vivo ferroptosis and cancer growth suppression.
Our data link the GPX1-OSBPL8 axis to in vivo ferroptosis and tumor suppression.
TL;DR
Our data link the GPX1-OSBPL8 axis to in vivo ferroptosis and tumor suppression.
Key findings
- OSBPL8 and GPX1 are overexpressed in cancers; knockdown of either promotes ROS-induced ferroptosis and suppresses tumor growth.
- Our data link the GPX1-OSBPL8 axis to in vivo ferroptosis and tumor suppression.
What they did
We identify GPX1 as a key regulator of this ROS-induced ferroptosis by modulating PA peroxidation. GPX1's effects depend on OSBPL8, an endoplasmic reticulum (ER)-membrane-associated oxysterol-binding protein. ROS-driven lipid peroxidation accumulates at the ER before plasma membrane rupture and cell death; GPX1 is recruited to the ER via OSBPL8 and directly reduces oxidized PA.
Full abstract (original)
Background: Ferroptosis is a tumor-suppressive mechanism with therapeutic potential. While canonical ferroptosis is usually triggered by inducers, such as erastin and RSL-3, or by glutathione peroxidase (GPX)4 loss, how ferroptosis occurs naturally in vivo without these triggers has been unclear. Building on evidence that p53 can mediate ferroptosis as a natural tumor-suppressive pathway, we describe a noncanonical, in vivo ferroptosis driven by reactive oxygen species (ROS)-induced phosphatidic acid (PA) peroxidation that proceeds without inducers.
What they did: We identify GPX1 as a key regulator of this ROS-induced ferroptosis by modulating PA peroxidation. GPX1's effects depend on OSBPL8, an endoplasmic reticulum (ER)-membrane-associated oxysterol-binding protein. ROS-driven lipid peroxidation accumulates at the ER before plasma membrane rupture and cell death; GPX1 is recruited to the ER via OSBPL8 and directly reduces oxidized PA.
Results & conclusions: OSBPL8 and GPX1 are overexpressed in cancers; knockdown of either promotes ROS-induced ferroptosis and suppresses tumor growth. Our data link the GPX1-OSBPL8 axis to in vivo ferroptosis and tumor suppression.
Abstract © the authors / Cell (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.cell.2026.01.009 · PubMed 41720096.
Why it matters for pharma & biotech
- Relevant to General & Medicine teams tracking Cell for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Cell study find?
Our data link the GPX1-OSBPL8 axis to in vivo ferroptosis and tumor suppression.
What type of study is this?
It is a research study, published in Cell in 2026. We identify GPX1 as a key regulator of this ROS-induced ferroptosis by modulating PA peroxidation.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.cell.2026.01.009. PubMed ID: 41720096. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/a-gpx1-osbpl8-axis-mediates-noncanonical-in-vivo-ferroptosis-and-cancer-601009/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides